News

Based on current evidence, the Task Force was unable to recommend cognitive screening for older adults despite a recent push by the AAN to screen all adults 65 and older for thinking and memory problems.

New study data from ISC 2020 suggest that patients with stroke can be effectively treated with tenecteplase at a lower dose of 0.25 mg/kg, reducing the need for mechanical clot removal.

Two new classes of medications have quickly expanded the pool of available treatment options for patients with migraine, who now have more power than ever to choose the treatment that fits them best.

The VMAT2 inhibitor failed to meet the primary end point in the ARTISTS 1 and ARTISTS 2 trials in the treatment of tics in pediatric patients with Tourette syndrome.

Stroke patients experienced higher rates of thrombolysis as well as faster alarm to treatment times when mobile stroke units were present.

The novel B-cell therapy has been assigned a PDUFA date of June 2020.

The composite primary end point of the study occurred in 9.6% of patients in the lower-target LDL-C group compared with 12.9% in the higher target group.

Retrotope had already received FDA approval to test RT001, a chemically modified polyunsaturated fatty acid agent, in expanded access trials of 3 patients with progressive supranuclear palsy.

Eptinezumab, Lundbeck’s intravenous monoclonal antibody that will be marketed as Vyepti, will become available for prescription in April 2020 with a recommended dose of 100 mg quarterly.

The chief science officer at the Alzheimer's Drug Discovery Foundation discussed the resource, which consists of more than 200 reports on drugs, development, supplements, food/drink, nonpharmacologics, and risk factors related to brain health.

Neurology News Network for the week ending February 22, 2020.

Despite missing the primary end point, data from a subset of patients suggest that the novel peptide may be beneficial in those who have not received alteplase.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 21, 2020.

Phenytoin is indicated for the treatment of tonic-clonic and psychomotor seizures in pediatric and adult patients.

The previously approved therapy is now indicated for treatment in pediatric patients age 2 to 10.

New data suggest a switch from natalizumab to a high efficacy disease-modifying therapy for patients with multiple sclerosis is more beneficial than switching to moderate efficacy therapy, including a lower risk of disease activity.

Despite the conventional need for patients to travel to MRI devices, the use of a point-of-care, portable scanner has proven to be a feasible method of acquiring clinically useful images.

Secondary endpoints and final results from the clinical study will be announced at the end of March 2020.